
<http://bio2rdf.org/drugbank:DB00051> a <http://schema.org/Drug> ;
	<http://schema.org/name> "Adalimumab" ;
	<http://schema.org/description> "Adalimumab is a human monoclonal antibody against TNF-alpha. It is produced by recombinant DNA technology using a mammalian cell expression system. It consists of 1330 amino acids and has a molecular weight of approximately 148 kilodaltons." ;
	<http://schema.org/url> "https://www.drugbank.ca/drugs/DB00051" ;
	<http://schema.org/doseSchedule> "40 mg/.8mL Injection, solution form with subcutaneous route" ;
	<http://schema.org/legalStatus> "approved" ;
	<http://schema.org/mechanismOfAction> "Adalimumab binds to TNF-alpha and blocks its interaction with the p55 and p75 cell surface TNF receptors. Adalimumab also lyses surface TNF expressing cells in vitro in the presence of complement." ;
	<http://schema.org/alternateName> "Ig gamma-1 chain C region" ;
	<http://schema.org/sameAs> "https://www.drugbank.ca/drugs/DB00051" .
